yego.me
💡 Stop wasting time. Read Youtube instead of watch. Download Chrome Extension

The Challenges with Cancer Trials | Breakthrough


2m read
·Nov 11, 2024

ANDRE CHOULIKA: We didn't have any intention of injecting these type of vials to patient because we needed a lot of vials to be able to file our clinical trial application. And this was planned to be done with the University College London.

NARRATOR: Before any new medication or therapy is considered safe and effective, it must first be rigorously tested through clinical trials. These trials are fundamental in determining an experimental treatment's dosage and safety and to identify any possible side effects. At the University College London, Great Ormond Street Institute of Child Health, Professor Waseem Qasim was working with Cellectis as the principal investigator, taking the universal CAR T-cells from the lab to trials.

Normally, this process can take over a decade, with nearly endless layers of approval. So our questions were what do you do if your patient is already so unwell that you can't collect cells; or has had so much chemotherapy that there's no white blood cells left to collect, that you think are going to be useful; how do you do this process in a way that can be done quickly and delivered back to the patient in a timely manner?

And the answer to that is perhaps being able to use a product, a cell product, that's been made beforehand, that can be given back to multiple patients. Now in order to do that, we have to overcome the barrier of transplantation, which means if I put my cells into a nonmatched individual, the cells firstly will want to react against that individual because they will know the individuals is foreign. And secondly, the person receiving the cells will try and reject them because they know the cells are not their own.

NARRATOR: In affiliation with Professor Qasim, Doctor Paul Veys works on the front line with patients who desperately need new cancer treatment options. I'll have treated well over 3,000 patients and at least 600 of those will have gone wrong. So there's a lot of patients that we lose. It's unsuccessful. You've got to be able to come in the next day. Even from our failures, we've learned lots. And if we hadn't gone through those failures, we wouldn't be having some of the successes we have today.

Has the chest always been good? He's not had any big chest infections? NURSE: No. It's not good. Let's warm it up. Sit forward again. Yeah. Perfect. OK. Big breaths.

More Articles

View All
Symmetry of second partial derivatives
So in the last couple videos I talked about partial derivatives of multivariable functions, and here I want to talk about second partial derivatives. So, I’m going to write some kind of multivariable function. Let’s say it’s, um, I don’t know, sin of x * …
This Plan to Save a Rare Albatross From Extinction Just Might Work | National Geographic
There’s a place called the Pyramid Tatara Khoikhoi, yeah, off the Chatham Islands. This one rock basically is the only place in the world where this exceptionally beautiful, extremely rare bird breeds. The entire global population of 5,000 something pairs…
Lecture 6 - Growth (Alex Schultz)
Thank you for oversold. Thank you, um, cool. So, you guys, uh, this is awesome! I’ve been watching the lectures in this course. Isn’t it absolutely amazing, the content? And now, you’re stuck with me today. We’ll see how that goes. Um, so, uh, unlike Paul…
Charlie Munger is selling Alibaba!
If you’ve been following this channel for any amount of time, you know I’m a big believer that one of the best ways to learn about investing is to follow the portfolios of well-respected investors. Whether you are just starting out on your investing journ…
YC Tech Talks: MMOs in the Instagram Era: Highrise (S18)
Um, hi everybody. I’m Jimmy. I’m the co-founder and CTO of Pocket Worlds, where Highrise is. We built Highrise, the app which is available on iOS and Android, and I think to date it has over 5 million downloads, and we’re grossing over a million a month i…
Can Stoics Be Activists? | Q&A #5 | July 2019
Hello everyone! Welcome to the fifth Einzelgänger Q&A. Before the weekend, I reached the 50,000 subscriber mark on this channel. When I started back in January, I’d never had expected that this channel would reach this magic number so quickly or, at a…